W. Hartwig, O. Strobel, U. Hinz, S. Fritz i inni. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. „Ann Surg Oncol”. 20 (7), s. 2188-96, Jul 2013. DOI: 10.1245/s10434-012-2809-1. PMID: 23247983.
YC. Kim, HJ. Kim, JH. Park, DI. Park i inni. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?. „J Gastroenterol Hepatol”. 24 (12), s. 1869-75, Dec 2009. DOI: 10.1111/j.1440-1746.2009.05935.x. PMID: 19686409.
CR. Ferrone, DM. Finkelstein, SP. Thayer, A. Muzikansky i inni. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. „J Clin Oncol”. 24 (18), s. 2897-902, Jun 2006. DOI: 10.1200/JCO.2005.05.3934. PMID: 16782929.
AC. Berger, M. Garcia, JP. Hoffman, WF. Regine i inni. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. „J Clin Oncol”. 26 (36), s. 5918-22, Dec 2008. DOI: 10.1200/JCO.2008.18.6288. PMID: 19029412.
CW. Tzeng, A. Balachandran, M. Ahmad, JE. Lee i inni. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. „HPB (Oxford)”. 16 (5), s. 430-8, May 2014. DOI: 10.1111/hpb.12154. PMID: 23991810.
G. Malaguarnera, I. Paladina, M. Giordano, M. Malaguarnera i inni. Serum markers of intrahepatic cholangiocarcinoma. „Dis Markers”. 34 (4), s. 219-28, 2013. DOI: 10.3233/DMA-130964. PMID: 23396291.
N. Chalasani, A. Baluyut, A. Ismail, A. Zaman i inni. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. „Hepatology”. 31 (1), s. 7-11, Jan 2000. DOI: 10.1002/hep.510310103. PMID: 10613720.
YL. Chen, CH. Chen, RH. Hu, MC. Ho i inni. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection. „ScientificWorldJournal”. 2013, s. 380797, 2013. DOI: 10.1155/2013/380797. PMID: 23843733.
P. Wan, J. Zhang, X. Long, Q. Li i inni. Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. „Eur J Gastroenterol Hepatol”. 26 (5), s. 553-61, May 2014. DOI: 10.1097/MEG.0000000000000070. PMID: 24589829.
CC. Hsu, A. Goyal, A. Iuga, S. Krishnamoorthy i inni. Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients. „Clin Transl Gastroenterol”. 6, s. e74, 2015. DOI: 10.1038/ctg.2014.22. PMID: 25651978.
M. Swiderska, B. Choromańska, E. Dąbrowska, E. Konarzewska-Duchnowska i inni. The diagnostics of colorectal cancer. „Contemp Oncol (Pozn)”. 18 (1), s. 1-6, 2014. DOI: 10.5114/wo.2013.39995. PMID: 24876814.
B. Levin, DA. Lieberman, B. McFarland, KS. Andrews i inni. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. „Gastroenterology”. 134 (5), s. 1570-95, May 2008. DOI: 10.1053/j.gastro.2008.02.002. PMID: 18384785.
Z. Vukobrat-Bijedic, A. Husic-Selimovic, A. Sofic, N. Bijedic i inni. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma. „Med Arch”. 67 (6), s. 397-401, Dec 2013. DOI: 10.5455/medarh.2013.67.397-401. PMID: 25568506.
J. Stiksma, DC. Grootendorst, PW. van der Linden. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. „Clin Colorectal Cancer”. 13 (4), s. 239-44, Dec 2014. DOI: 10.1016/j.clcc.2014.09.004. PMID: 25442815.
Y. Narita, H. Taniguchi, A. Komori, S. Nitta i inni. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. „Cancer Chemother Pharmacol”. 73 (2), s. 409-16, Feb 2014. DOI: 10.1007/s00280-013-2367-7. PMID: 24322376.
MJ. Gaspar, I. Arribas, MC. Coca, M. Díez-Alonso. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. „Tumour Biol”. 22 (5). s. 318-22. DOI: 10.1159/000050633. PMID: 11553862.
E. Ucar, E. Semerci, H. Ustun, T. Yetim i inni. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. „Adv Ther”. 25 (10), s. 1075-84, Oct 2008. DOI: 10.1007/s12325-008-0100-4. PMID: 18821070.
M. Scarpa, G. Noaro, L. Saadeh, F. Cavallin i inni. Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma. „World J Surg”. 39 (2), s. 424-32, Feb 2015. DOI: 10.1007/s00268-014-2835-1. PMID: 25326423.
W. Hartwig, O. Strobel, U. Hinz, S. Fritz i inni. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. „Ann Surg Oncol”. 20 (7), s. 2188-96, Jul 2013. DOI: 10.1245/s10434-012-2809-1. PMID: 23247983.
YC. Kim, HJ. Kim, JH. Park, DI. Park i inni. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?. „J Gastroenterol Hepatol”. 24 (12), s. 1869-75, Dec 2009. DOI: 10.1111/j.1440-1746.2009.05935.x. PMID: 19686409.
CR. Ferrone, DM. Finkelstein, SP. Thayer, A. Muzikansky i inni. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. „J Clin Oncol”. 24 (18), s. 2897-902, Jun 2006. DOI: 10.1200/JCO.2005.05.3934. PMID: 16782929.
AC. Berger, M. Garcia, JP. Hoffman, WF. Regine i inni. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. „J Clin Oncol”. 26 (36), s. 5918-22, Dec 2008. DOI: 10.1200/JCO.2008.18.6288. PMID: 19029412.
CW. Tzeng, A. Balachandran, M. Ahmad, JE. Lee i inni. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. „HPB (Oxford)”. 16 (5), s. 430-8, May 2014. DOI: 10.1111/hpb.12154. PMID: 23991810.
G. Malaguarnera, I. Paladina, M. Giordano, M. Malaguarnera i inni. Serum markers of intrahepatic cholangiocarcinoma. „Dis Markers”. 34 (4), s. 219-28, 2013. DOI: 10.3233/DMA-130964. PMID: 23396291.
XL. Qin, ZR. Wang, JS. Shi, M. Lu i inni. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. „World J Gastroenterol”. 10 (3), s. 427-32, Feb 2004. PMID: 14760772.
N. Chalasani, A. Baluyut, A. Ismail, A. Zaman i inni. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. „Hepatology”. 31 (1), s. 7-11, Jan 2000. DOI: 10.1002/hep.510310103. PMID: 10613720.
JK. Ramage, A. Donaghy, JM. Farrant, R. Iorns i inni. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. „Gastroenterology”. 108 (3), s. 865-9, Mar 1995. PMID: 7875490.
WF. Shen, W. Zhong, F. Xu, T. Kan i inni. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. „World J Gastroenterol”. 15 (47), s. 5976-82, Dec 2009. PMID: 20014463.
B. Juntermanns, S. Radunz, M. Heuer, S. Hertel i inni. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. „Eur J Med Res”. 15 (8), s. 357-61, Aug 2010. PMID: 20947473.
S. Maestranzi, R. Przemioslo, H. Mitchell, RA. Sherwood. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. „Ann Clin Biochem”. 35 ( Pt 1), s. 99-103, Jan 1998. PMID: 9463746.
LY. Tao, L. Cai, XD. He, W. Liu i inni. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. „Am Surg”. 76 (11), s. 1210-3, Nov 2010. PMID: 21140686.
YL. Chen, CH. Chen, RH. Hu, MC. Ho i inni. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection. „ScientificWorldJournal”. 2013, s. 380797, 2013. DOI: 10.1155/2013/380797. PMID: 23843733.
P. Wan, J. Zhang, X. Long, Q. Li i inni. Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. „Eur J Gastroenterol Hepatol”. 26 (5), s. 553-61, May 2014. DOI: 10.1097/MEG.0000000000000070. PMID: 24589829.
CC. Hsu, A. Goyal, A. Iuga, S. Krishnamoorthy i inni. Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients. „Clin Transl Gastroenterol”. 6, s. e74, 2015. DOI: 10.1038/ctg.2014.22. PMID: 25651978.
M. Swiderska, B. Choromańska, E. Dąbrowska, E. Konarzewska-Duchnowska i inni. The diagnostics of colorectal cancer. „Contemp Oncol (Pozn)”. 18 (1), s. 1-6, 2014. DOI: 10.5114/wo.2013.39995. PMID: 24876814.
B. Levin, DA. Lieberman, B. McFarland, KS. Andrews i inni. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. „Gastroenterology”. 134 (5), s. 1570-95, May 2008. DOI: 10.1053/j.gastro.2008.02.002. PMID: 18384785.
SY. Zhang, M. Lin, HB. Zhang. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma. „Int J Clin Exp Pathol”. 8 (8), s. 9404-9, 2015. PMID: 26464695.
R. Partyka, A. Sandelewski, I. Łobejko, J. Kocot i inni. Usefulness of evaluation of soluble fragment cytokeratin 18, carcinoembryonic antigen and gastrointestinal carcinoma-associated antigen in diagnostic of patients with colorectal cancer. „Pol Merkur Lekarski”. 29 (170), s. 128-30, Aug 2010. PMID: 20842828.
Z. Vukobrat-Bijedic, A. Husic-Selimovic, A. Sofic, N. Bijedic i inni. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma. „Med Arch”. 67 (6), s. 397-401, Dec 2013. DOI: 10.5455/medarh.2013.67.397-401. PMID: 25568506.
SG. Yeo, DY. Kim, TH. Kim, SY. Kim i inni. Carbohydrate antigen 19-9 levels associated with pathological responses to preoperative chemoradiotherapy in rectal cancer. „Asian Pac J Cancer Prev”. 15 (13), s. 5383-7, 2014. PMID: 25041006.
J. Stiksma, DC. Grootendorst, PW. van der Linden. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. „Clin Colorectal Cancer”. 13 (4), s. 239-44, Dec 2014. DOI: 10.1016/j.clcc.2014.09.004. PMID: 25442815.
Y. Narita, H. Taniguchi, A. Komori, S. Nitta i inni. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. „Cancer Chemother Pharmacol”. 73 (2), s. 409-16, Feb 2014. DOI: 10.1007/s00280-013-2367-7. PMID: 24322376.
M. Ychou, J. Duffour, A. Kramar, S. Gourgou i inni. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. „Dis Markers”. 16 (3-4), s. 105-10, 2000. PMID: 11381189.
MJ. Gaspar, I. Arribas, MC. Coca, M. Díez-Alonso. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. „Tumour Biol”. 22 (5). s. 318-22. DOI: 10.1159/000050633. PMID: 11553862.
E. Dilege, M. Mihmanli, U. Demir, K. Ozer i inni. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. „Hepatogastroenterology”. 57 (99-100). s. 674-7. PMID: 20698248.
E. Ucar, E. Semerci, H. Ustun, T. Yetim i inni. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. „Adv Ther”. 25 (10), s. 1075-84, Oct 2008. DOI: 10.1007/s12325-008-0100-4. PMID: 18821070.
E. Munck-Wikland, R. Kuylenstierna, J. Lindholm, B. Wahren. Carcinoembryonic antigen, CA 19-9 and CA 50 in monitoring human squamous cell carcinoma of the esophagus. „Anticancer Res”. 10 (3). s. 703-8. PMID: 2369087.
M. Scarpa, G. Noaro, L. Saadeh, F. Cavallin i inni. Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma. „World J Surg”. 39 (2), s. 424-32, Feb 2015. DOI: 10.1007/s00268-014-2835-1. PMID: 25326423.
S. Rakic, V. Kalezic, G. Grujic-Adanja, M. Jagodic. Pretreatment levels of CEA, CA 19-9, CA 50 and CA 72-4 in sera of patients with squamous cell carcinoma of the oesophagus. „Eur J Cancer Prev”. 2 (4), s. 361, Jul 1993. PMID: 8358290.
